^
BIOMARKER:

BRCA2 mutation

i
Other names: BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
Entrez ID:
Related biomarkers:
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
AstraZeneca Press Release - 6 days
BRCA2 mutation
Ovarian Cancer
pamiparib
Sensitive: A1 - Approval
Clin Cancer Res - 1 week
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Cancer Discov - 2 weeks
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
BRCA2 mutation
Fallopian Tube Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
BRCA2 mutation
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
BRCA2 mutation
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Ovarian Cancer
olaparib + bevacizumab
Sensitive: A1 - Approval
BRCA2 mutation
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
BRCA2 mutation
Peritoneal Cancer
pamiparib
Sensitive: A1 - Approval
BRCA2 mutation
Fallopian Tube Cancer
pamiparib
Sensitive: A1 - Approval
BRCA2 mutation
Breast Cancer
olaparib
Sensitive: A2 - Guideline
BRCA2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
BRCA2 mutation
Ovarian Cancer
bevacizumab
Resistant: A2 - Guideline
BRCA2 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
BRCA2 mutation
Breast Cancer
talazoparib
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
BRCA2 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
BRCA2 mutation
Ovarian Cancer
trabectedin
Sensitive: B - Late Trials
BRCA2 mutation
Prostate Cancer
niraparib
Sensitive: B - Late Trials
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin + paclitaxel
Sensitive: B - Late Trials
BRCA2 mutation
Triple Negative Breast Cancer
ABT-888
Sensitive: B - Late Trials
BRCA2 mutation
HER2 Negative Breast Cancer
ABT-888
Sensitive: B - Late Trials
BRCA2 mutation
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
olaparib + cediranib
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
PARP inhibitor
Sensitive: B - Late Trials
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
ABT-888
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
fluzoparib
Sensitive: B - Late Trials
BRCA2 mutation
Breast Cancer
ribociclib
Sensitive: B - Late Trials
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
atezolizumab
Resistant: B - Late Trials
BRCA2 mutation
Ovarian Cancer
CPB
Sensitive: B - Late Trials
BRCA2 mutation
Ovarian Cancer
rucaparib
Resistant: B - Late Trials
BRCA2 mutation
HER2 Negative Breast Cancer
niraparib
Sensitive: B - Late Trials
BRCA2 mutation
NSCLC
rucaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Pancreatic Cancer
rucaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Cholangiocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Triple Negative Breast Cancer
niraparib
Sensitive: C1 - Off-label
BRCA2 mutation
Endometrial Cancer
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Ovarian Serous Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Prostate Cancer
talazoparib
Sensitive: C1 - Off-label
BRCA2 mutation
CRC
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Urothelial Cancer
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Triple Negative Breast Cancer
pamiparib
Sensitive: C1 - Off-label
BRCA2 mutation
Ovarian Cancer
talazoparib
Sensitive: C1 - Off-label
BRCA2 mutation
RCC
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Biliary Tract Cancer
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
Pancreatic Cancer
ABT-888
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Breast Cancer
olaparib + AZD5363
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Breast Cancer
ABT-888
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Ovarian Cancer
olaparib + bevacizumab + durvalumab
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
HER2 Negative Breast Cancer
carboplatin + paclitaxel
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Ovarian Cancer
IMP4297
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib + durvalumab
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Ovarian Cancer
ABT-888
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Ovarian Cancer
olaparib + CP-675206
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Ovarian Cancer
SC10914
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Ovarian Cancer
tislelizumab + pamiparib
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Ovarian Cancer
olaparib + durvalumab + CP-675206
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Triple Negative Breast Cancer
tislelizumab
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Triple Negative Breast Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Solid Tumor
avelumab
Sensitive: C2 – Inclusion Criteria
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine + eribulin mesylate
Resistant: C3 – Early Trials
BRCA2 mutation
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
BRCA2 mutation
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib + AZD6738
Sensitive: C3 – Early Trials
BRCA2 mutation
Hormone Receptor Positive Breast Cancer
fulvestrant + anastrozole
Resistant: C3 – Early Trials
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA2 mutation
Bladder Cancer
cisplatin
Sensitive: C3 – Early Trials
BRCA2 mutation
Prostate Cancer
carboplatin
Sensitive: C3 – Early Trials
BRCA2 mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
BRCA2 mutation
Pancreatic Cancer
oxaliplatin
Sensitive: C3 – Early Trials
BRCA2 mutation
Prostate Cancer
PARP inhibitor
Sensitive: C3 – Early Trials
BRCA2 mutation
Head and Neck Cancer
AZD1775
Sensitive: C3 – Early Trials